Oncology Institute (TOI) Non-Current Deffered Revenue (2020 - 2021)
Oncology Institute (TOI) reported Non-Current Deffered Revenue of $6.3 million for Q3 2021, little changed on a YoY basis from $6.3 million in Q3 2020, and little changed quarter-over-quarter from $6.3 million in Q2 2021.
Oncology Institute (TOI) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Oncology Institute has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $6.3 million in Q3 2021.
- For the quarter ending Q3 2021, Non-Current Deffered Revenue changed 0.0% year-over-year to $6.3 million; the trailing twelve-month figure through Sep 2021 stood at $6.3 million (changed 0.0% YoY), and the FY2020 full-year result was $6.3 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2021 stood at $6.3 million, roughly flat from $6.3 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $6.3 million in Q1 2020, with the low at $6.3 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 83.85 Bn | 86.23 Bn | 16.26 Bn | - |
| 2 | Tenet Healthcare | 14.98 Bn | 14.15 Bn | 4.41 Bn | - |
| 3 | Davita | 13.99 Bn | 14.84 Bn | 1.07 Bn | - |
| 4 | Encompass Health | 9.72 Bn | 10.34 Bn | 1.34 Bn | - |
| 5 | Ensign | 8.90 Bn | 8.31 Bn | 293.37 Mn | 86.28 Mn |
| 6 | Universal Health Services | 8.59 Bn | 8.55 Bn | 3.21 Bn | - |
| 7 | Fresenius Medical Care AG | 7.67 Bn | 5.29 Bn | -4.26 Bn | - |
| 8 | Chemed | 5.97 Bn | 5.96 Bn | 215.76 Mn | 142.66 Mn |
| 9 | Pacs | 5.74 Bn | 5.50 Bn | 345.96 Mn | - |
| 10 | Oncology Institute | 535.99 Mn | 505.71 Mn | 139.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6.30 Mn |
| Jun 30, 2021 | 6.30 Mn |
| Mar 31, 2021 | 6.30 Mn |
| Dec 31, 2020 | 6.30 Mn |
| Sep 30, 2020 | 6.30 Mn |
| Jun 30, 2020 | 6.30 Mn |
| Mar 13, 2020 | 6.30 Mn |